Date:2/23/2009

apital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

IMPORTANT INFORMATION/SOLICITATION PARTICIPANTS LEGEND

Vanda Pharmaceuticals and its d
'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
2. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
3. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
4. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
5. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
6. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
7. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
8. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
9. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results